ATE419858T1 - Krillextrakte zur prävention und/oder behandlung von herz-kreislauf-erkrankungen - Google Patents

Krillextrakte zur prävention und/oder behandlung von herz-kreislauf-erkrankungen

Info

Publication number
ATE419858T1
ATE419858T1 AT02734945T AT02734945T ATE419858T1 AT E419858 T1 ATE419858 T1 AT E419858T1 AT 02734945 T AT02734945 T AT 02734945T AT 02734945 T AT02734945 T AT 02734945T AT E419858 T1 ATE419858 T1 AT E419858T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
cardiovascular diseases
krill
relates
Prior art date
Application number
AT02734945T
Other languages
English (en)
Inventor
Tina Sampalis
Original Assignee
Neptune Technologies & Bioress
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23150259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE419858(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neptune Technologies & Bioress filed Critical Neptune Technologies & Bioress
Application granted granted Critical
Publication of ATE419858T1 publication Critical patent/ATE419858T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Insects & Arthropods (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
AT02734945T 2001-06-18 2002-06-07 Krillextrakte zur prävention und/oder behandlung von herz-kreislauf-erkrankungen ATE419858T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29838301P 2001-06-18 2001-06-18

Publications (1)

Publication Number Publication Date
ATE419858T1 true ATE419858T1 (de) 2009-01-15

Family

ID=23150259

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02734945T ATE419858T1 (de) 2001-06-18 2002-06-07 Krillextrakte zur prävention und/oder behandlung von herz-kreislauf-erkrankungen
AT08164524T ATE554779T1 (de) 2001-06-18 2002-06-07 Krill zur prävention und/oder behandlung von herz-kreislauf-erkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08164524T ATE554779T1 (de) 2001-06-18 2002-06-07 Krill zur prävention und/oder behandlung von herz-kreislauf-erkrankungen

Country Status (14)

Country Link
US (5) US20040241249A1 (de)
EP (2) EP1997498B1 (de)
JP (4) JP5135568B2 (de)
CN (2) CN1516592A (de)
AT (2) ATE419858T1 (de)
CA (1) CA2449898C (de)
CY (1) CY1108986T1 (de)
DE (1) DE60230759D1 (de)
DK (2) DK1406641T3 (de)
ES (2) ES2321066T3 (de)
HK (2) HK1126957A1 (de)
NO (1) NO332690B1 (de)
PT (1) PT1406641E (de)
WO (1) WO2002102394A2 (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60220415T2 (de) 2001-07-27 2008-02-14 Neptune Technologies & Bioressources Inc., Laval Flavonoide und mehrfach ungesättigte fettsäuren enthaltende natürliche phospholipide maritimen ursprungs sowie deren anwendungen
AU2013205515B2 (en) * 2001-07-27 2015-07-02 Aker Biomarine Antarctic As Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
DE602004020316D1 (de) * 2003-01-20 2009-05-14 Tno Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.
GB0314624D0 (en) 2003-06-23 2003-07-30 Advanced Bionutrition Europ Lt Inflammatory disease treatment
FR2859380B1 (fr) * 2003-09-05 2006-02-10 Phythea Composition destinee au traitement cosmetique de la peau d'un etre humain
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
CA2544235C (en) 2003-10-28 2013-12-10 Emory University Dialysates and methods and systems related thereto
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2005075613A1 (en) * 2004-02-06 2005-08-18 Adrien Beaudoin Method for preventing the oxidation of lipids in animal and vegetable oils and compositions produced by the method thereof
DE602005026785D1 (de) * 2004-03-16 2011-04-21 Tno Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
AU2005310341A1 (en) 2004-11-30 2006-06-08 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae
JP2006016408A (ja) * 2005-06-23 2006-01-19 Yamaha Motor Co Ltd 血中中性脂肪抑制剤
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
WO2007045407A2 (en) * 2005-10-18 2007-04-26 Artmed S.R.L. Nutraceutical and pharmaceutical compositions containing choline as adiuvants for the prevention and treatment of retinopathies and glaucoma
AR059012A1 (es) * 2006-01-13 2008-03-05 Aker Biomarine Asa Extractos derivados del krill
EP1996686A1 (de) * 2006-02-07 2008-12-03 Universitetet I Oslo Omega 3
CA2657748C (en) * 2006-07-14 2014-10-21 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
MX2009004339A (es) * 2006-11-03 2009-05-20 Pronova Biopharma Norge As Alcoholes de acido graso.
KR101578498B1 (ko) 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 신경 재생제
AU2014100735B4 (en) * 2007-03-28 2014-09-11 Aker Biomarine Antarctic As Processes and products thereof
AU2011213836B2 (en) * 2007-03-28 2013-11-14 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
EP2144618B1 (de) 2007-03-28 2013-05-15 Aker Biomarine ASA Biologisch wirksame krill-öl-zusammensetzungen
AU2012244229B2 (en) * 2007-08-29 2013-11-21 Aker Biomarine Antarctic As A new method for making krill meal
AU2014100741B4 (en) * 2007-08-29 2014-09-11 Aker Biomarine Antarctic As Processes and products thereof
AU2008291978B2 (en) * 2007-08-29 2012-08-09 Aker Biomarine Antarctic As A new method for making krill meal
US20100226977A1 (en) * 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
US8911888B2 (en) 2007-12-16 2014-12-16 HGST Netherlands B.V. Three-dimensional magnetic memory with multi-layer data storage layers
US8586104B2 (en) * 2008-04-10 2013-11-19 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essentially fatty acids derived from Salvia hispanica L. seed: composition of matter, manufacturing process and use
MX2010012482A (es) * 2008-05-15 2010-12-01 Pronova Biopharma Norge As Proceso para aceite de kril.
US9239334B2 (en) * 2008-09-08 2016-01-19 President And Fellows Of Harvard College Fatty acid C16: 1N7-palmitoleate a lipokine and biomarker for metabolic status
ES2939304T3 (es) 2008-09-12 2023-04-20 Rimfrost Tech As Fracción concentrada de hidrolizado de proteína de kril
US8557297B2 (en) 2008-09-12 2013-10-15 Olympic Seafood, As Method for processing crustaceans and products thereof
US9814256B2 (en) 2009-09-14 2017-11-14 Rimfrost Technologies As Method for processing crustaceans to produce low fluoride/low trimethyl amine products thereof
KR101024491B1 (ko) * 2008-12-31 2011-03-31 인성실업(주) 해양 동물로부터 지질을 추출하는 방법
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
JP2010241710A (ja) * 2009-04-02 2010-10-28 Japan Health Science Foundation Ａｃｅ２活性誘導剤
CA2795907A1 (en) 2009-04-09 2010-10-14 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for inducing physiological hypertrophy
WO2010136900A2 (en) 2009-05-28 2010-12-02 Aker Biomarine Asa Methods of using krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
US9913810B2 (en) 2009-07-23 2018-03-13 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and astaxanthin
US8481072B2 (en) 2009-07-23 2013-07-09 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
US9402857B2 (en) 2009-07-23 2016-08-02 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US9238043B2 (en) 2009-07-23 2016-01-19 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using algae based oils
US9399047B2 (en) 2009-07-23 2016-07-26 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and roe extract
US9216164B2 (en) 2009-07-23 2015-12-22 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US8557275B2 (en) * 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
PT2493478T (pt) * 2009-10-29 2018-04-03 Acasti Pharma Inc Composições terapêuticas concentradas de fosfolípidos
CA2779334C (en) * 2009-10-30 2017-05-30 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
US8415506B2 (en) * 2009-11-11 2013-04-09 Dynasep Inc. Energy efficient acetone drying method
US20110117207A1 (en) * 2009-11-17 2011-05-19 U.S. Nutraceuticals, LLC d/b/a Valensa International State of Incorporation: Use of eggshell membrane formulations to alleviate joint pain
US9763897B2 (en) 2010-04-30 2017-09-19 U.S. Nutraceuticals, LLC Therapeutic astaxanthin and phospholipid composition and associated method
WO2011137160A2 (en) 2010-04-30 2011-11-03 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
US8663704B2 (en) 2010-04-30 2014-03-04 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
WO2012029898A1 (ja) * 2010-09-01 2012-03-08 日本水産株式会社 アルコール性障害緩和剤
KR20120051458A (ko) * 2010-11-12 2012-05-22 주식회사 두산 크릴 인지질을 이용하여 아스타잔틴 및 ｄｈａ－ 및/또는 ｅｐａ－결합된 포스파티딜세린을 함유한 조성물을 제조하는 방법 및 이러한 방법에 의해 제조된 조성물
CN102485899A (zh) * 2010-12-03 2012-06-06 张永志 一种制备富含多不饱和双键脂肪酰基的磷脂酰丝氨酸的高品质南极磷虾油的方法
CN102041166B (zh) * 2011-01-20 2012-05-23 山东师范大学 从南极磷虾中提取高磷脂含量的虾油的方法
WO2012103685A1 (en) * 2011-02-01 2012-08-09 Nippon Suisan Kaisha, Ltd. Sexual function improving agent
KR101045258B1 (ko) * 2011-02-11 2011-06-30 대덕에프알디(주) 크릴 오일 제조 방법 및 상기 방법에 의해 제조된 크릴 오일
US20120231087A1 (en) * 2011-03-07 2012-09-13 Olympic Seafood Compositions And Methods for Nutritional Supplementation
BR112013032224B1 (pt) * 2011-06-15 2021-10-13 Stable Solutions Llc Composição farmacêutica aplicável parenteralmente
US10052352B2 (en) 2011-06-15 2018-08-21 Stable Solutions Llc Therapeutic application of parenteral krill oil
BR112013032410A2 (pt) * 2011-06-24 2017-01-17 Epitogenesis Inc composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
JP6067558B2 (ja) * 2011-06-29 2017-01-25 日本水産株式会社 恐怖記憶の軽減方法
US8846604B2 (en) 2011-09-02 2014-09-30 Artic Nutrition AS Lipid compositions with high DHA content
KR102153143B1 (ko) 2012-01-06 2020-09-08 옴테라 파마슈티칼스, 인크. 유리 산 형태의 오메가-3 다중불포화 지방산의 ｄｐａ-농축 조성물
CN102559371B (zh) * 2012-02-21 2013-09-18 山东师范大学 一种制备富含磷脂酰丝氨酸的虾油的方法
KR20150028233A (ko) 2012-05-07 2015-03-13 옴테라 파마슈티칼스, 인크. 스타틴 및 오메가-３ 지방산의 조성물
EP3591103A1 (de) 2012-09-07 2020-01-08 Japan Science and Technology Agency Gastverbindungsumhüllender polymer-metall-komplexkristall, verfahren zur herstellung davon, verfahren zur herstellung einer kristallstrukturanalyseprobe und verfahren zur bestimmung der molekularen strukturen einer organischen verbindung
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
CN102899163B (zh) * 2012-10-25 2015-03-25 山东师范大学 一种从南极磷虾中提取无氟虾油的工艺
CN102911786B (zh) * 2012-10-25 2014-01-08 山东师范大学 一种从南极磷虾中提取低氟含量的虾油的工艺
CN102925284B (zh) * 2012-10-25 2014-01-08 山东师范大学 一种从南极磷虾中提取低胆固醇含量的虾油的工艺
CN102899164B (zh) * 2012-10-25 2015-12-02 山东师范大学 一种制备无氟南极磷虾虾油的工艺
CN102899162B (zh) * 2012-10-25 2013-12-04 山东师范大学 一种制备低氟含量的南极磷虾虾油的工艺
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
WO2014184655A1 (en) 2013-02-07 2014-11-20 Olympic Seafood As Methods for using crustacean phospholipid-peptide-protein complexes
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
JP6393501B2 (ja) * 2014-04-03 2018-09-19 太陽化学株式会社 多価不飽和脂肪酸含有油脂の風味改善剤
CN105658073A (zh) 2013-10-08 2016-06-08 太阳化学株式会社 含多元不饱和脂肪酸的油脂组合物
JP2015096488A (ja) * 2013-10-10 2015-05-21 康二 嘉島 終末糖化物質生成抑制方法
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
WO2015142702A1 (en) 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using phospholipids and roe extract
KR20160144388A (ko) 2014-03-18 2016-12-16 유.에스. 뉴트라수티칼스, 엘.엘.씨. 저분자량 히알루론산 및 아스타잔틴을 사용하여 관절 통증을 완화하기 위한 조성물 및 방법
KR20160134787A (ko) 2014-03-18 2016-11-23 유.에스. 뉴트라수티칼스, 엘.엘.씨. 인지질 및 아스타잔틴을 사용하여 관절 통증을 완화하기 위한 조성물 및 방법
DE212015000033U1 (de) 2014-03-19 2016-08-26 U.S. Nutraceuticals, Llc D/B/A Valensa International Therapeutische Astaxanthin- und Phospholipidzusammensetzung
US10898525B2 (en) * 2014-04-30 2021-01-26 Aker Biomarine Antarctic As Krill oil preparations and their uses
JP6299689B2 (ja) * 2014-07-24 2018-03-28 三生医薬株式会社 生体吸収促進剤含有組成物
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
AU2015339576B2 (en) 2014-10-27 2020-02-06 Glytec, Llc Subcutaneous outpatient management
ES2937960T3 (es) 2015-02-11 2023-04-03 Aker Biomarine Antarctic As Proceso de extracción de lípidos
KR102310765B1 (ko) 2015-02-11 2021-10-12 에이커 바이오마린 앤탁틱 에이에스 지질 조성물
US10328105B2 (en) 2015-05-27 2019-06-25 Rimfrost Technologies As Flowable concentrated phospholipid krill oil composition
AU2016308953B2 (en) 2015-08-20 2020-09-10 Glytec, Llc Diabetes management therapy advisor
CN105341184A (zh) * 2015-10-14 2016-02-24 中国农业科学院油料作物研究所 一种具有预防心脑血管疾病和糖尿病风险因子作用的功能性油脂组合物
AU2016374158A1 (en) * 2015-12-14 2018-04-19 Société des Produits Nestlé S.A. Compositions and their use
DE202015106826U1 (de) * 2015-12-15 2016-02-03 Wolfgang Braun Zusammensetzung zur Behandlung von Prämenstruellem Syndrom
MX2018016091A (es) 2016-06-29 2019-09-16 Machavert Pharmaceuticals Llc Composiciones de fosfolipidos.
EP3534884A1 (de) * 2016-11-04 2019-09-11 Immd SP. Zo.o Intelligente abgabe von aufgenommenen und absorbierten molekülen
JP7309136B2 (ja) * 2017-04-14 2023-07-18 学校法人帝京大学 Ｈｄｌ機能改善剤及びｈｄｌ機能改善食品組成物
LT3727404T (lt) 2017-12-22 2023-10-25 Pharmalink International Limited Kompozicijos, apimančios midijų lipidų ekstraktą ir krilių aliejų bei jų medicininis taikymas
DE202018105987U1 (de) 2018-05-24 2018-12-19 U.S. Nutraceuticals, Llc D/B/A Valensa International Zusammensetzung zur Linderung von Gelenkschmerzen unter Verwendung von Hyaluronsäure und Eierschalenmembrankomponenten
JP2019210239A (ja) * 2018-06-02 2019-12-12 学校法人 岩手医科大学 ８−ヒドロキシエイコサペンタエン酸の薬理用途
DE202018105422U1 (de) 2018-06-21 2018-10-19 U.S. Nutraceuticals, Llc D/B/A Valensa International Zusammensetzung zur Linderung von Gelenkschmerzen unter Verwendung von Hyaluronsäure und Eierschalenmembrankomponenten
US20220265291A9 (en) * 2018-06-28 2022-08-25 Marizyme, Inc. Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices
WO2020006444A1 (en) * 2018-06-28 2020-01-02 Marizyme Biotech Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices
KR102085506B1 (ko) * 2018-07-25 2020-03-05 이경희 두피자극완화용 염모제 첨가조성물 및 두피자극완화용 염모제
EP4087582A1 (de) * 2020-01-10 2022-11-16 Acasti Pharma Inc. Zusammensetzung zur förderung pro-auflösender mediatoren
IT202000003964A1 (it) * 2020-02-26 2021-08-26 Umberto Cornelli Composizione farmaceutica per l’uso nel trattamento di dismenorrea e/o sindrome premestruale
KR102451162B1 (ko) * 2020-09-07 2022-10-06 (주)에스디생명공학 효소처리 크릴 오일 추출물을 유효성분으로 포함하는 항염증, 피부 주름개선, 보습 및 피부 재생 촉진용 조성물
CN112315984B (zh) * 2020-09-09 2023-02-14 山东省科学院生物研究所 海洋来源磷脂在促进血管生成方面的应用
CN112494499B (zh) * 2020-12-14 2022-01-28 山东省科学院生物研究所 海洋磷脂作为有效成分在制备预防和/或治疗心脏疾病药物中的应用
AU2022224703A1 (en) * 2021-09-28 2023-04-13 Samuel L. Shepherd Tetraterpenes for use in cancer therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54119017A (en) * 1978-03-06 1979-09-14 Taiyo Fishery Co Ltd Protective agent for hypertensive disease and production
JPS60153779A (ja) 1984-01-24 1985-08-13 Hohnen Oil Co Ltd 栄養補助食品
JPS6130527A (ja) * 1984-07-20 1986-02-12 Kao Corp 血栓溶解剤
JPS61118318A (ja) * 1984-11-12 1986-06-05 Pola Chem Ind Inc 血清脂質改善用組成物
JPS63295698A (ja) * 1987-05-27 1988-12-02 Showa Denko Kk α−リノレン酸の分離精製法
US4843095A (en) * 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
JPH01137952A (ja) * 1987-11-20 1989-05-30 Nippon Suisan Kaisha Ltd 健康食品
JPH02167055A (ja) * 1988-12-19 1990-06-27 Seiji Nojima 機能性練製品
JPH03123470A (ja) * 1989-10-05 1991-05-27 Taiyo Fishery Co Ltd オキアミ中のアンジオテンシン変換酵素阻害活性の増強法
JP2558050B2 (ja) * 1993-02-18 1996-11-27 イセ食品株式会社 鶏用飼料
JPH08219A (ja) * 1994-06-15 1996-01-09 Nippon Synthetic Chem Ind Co Ltd:The 機能の改善された油組成物
JP2666179B2 (ja) * 1994-08-10 1997-10-22 財団法人韓國食品開發研究院 抗高血圧健康食品組成物
JPH09124470A (ja) * 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物
JP3664814B2 (ja) * 1996-06-26 2005-06-29 旭化成ケミカルズ株式会社 血中脂質改善剤及び食品添加剤
JP3118556B2 (ja) * 1996-09-27 2000-12-18 中央水産研究所長 魚肉水溶性タンパク質により油脂を高濃度に含有させた魚肉乳化すり身及びその製造法
CA2251265A1 (en) * 1998-10-21 2000-04-21 Universite De Sherbrooke Process for lipid extraction of aquatic animal tissues producing a dehydrated residue

Also Published As

Publication number Publication date
US20040241249A1 (en) 2004-12-02
US20140199414A1 (en) 2014-07-17
JP5135568B2 (ja) 2013-02-06
ATE554779T1 (de) 2012-05-15
CA2449898A1 (en) 2002-12-27
NO332690B1 (no) 2012-12-10
ES2386841T3 (es) 2012-09-03
US20070098808A1 (en) 2007-05-03
EP1406641B1 (de) 2009-01-07
CN102319266A (zh) 2012-01-18
WO2002102394A3 (en) 2003-04-10
US20110305771A1 (en) 2011-12-15
JP5228185B2 (ja) 2013-07-03
US20170224742A1 (en) 2017-08-10
EP1997498A3 (de) 2009-06-03
HK1165729A1 (en) 2012-10-12
JP2010090140A (ja) 2010-04-22
US8057825B2 (en) 2011-11-15
PT1406641E (pt) 2009-04-15
DK1406641T3 (da) 2009-05-04
EP1997498B1 (de) 2012-04-25
JP2010090141A (ja) 2010-04-22
DK1997498T3 (da) 2012-07-30
EP1997498A2 (de) 2008-12-03
EP1406641A2 (de) 2004-04-14
WO2002102394A2 (en) 2002-12-27
JP2004534800A (ja) 2004-11-18
CY1108986T1 (el) 2014-07-02
CN102319266B (zh) 2014-12-17
NO20035618D0 (no) 2003-12-16
DE60230759D1 (de) 2009-02-26
HK1126957A1 (en) 2009-09-18
CA2449898C (en) 2018-03-06
ES2321066T3 (es) 2009-06-02
JP2013079278A (ja) 2013-05-02
CN1516592A (zh) 2004-07-28

Similar Documents

Publication Publication Date Title
ATE419858T1 (de) Krillextrakte zur prävention und/oder behandlung von herz-kreislauf-erkrankungen
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
CY1111359T1 (el) Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer
TNSN07208A1 (en) 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
NO20065227L (no) Menoklonale antistoff mot hepatocytt vekstfaktor
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
EA200301195A1 (ru) Применение энантиомерно чистого эсциталопрама
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
ATE438618T1 (de) Inhibitoren von humanem adam-10
WO2002066062A3 (en) Enhancement of glp-2 activity
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
DE60135904D1 (de) Arzneien zur behandlung von nervenerkrankungen
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
EA200200238A1 (ru) Терапевтический агент для диабета
ATE502637T1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
DE60213234D1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
WO2005044301A3 (en) Use of specific histones for the treatment of parasitic diseases
ATE398134T1 (de) Neue analoga von nitrobenzylthioinosin
EA200400296A1 (ru) Применение ингибиторов il-18 при расстройствах в виде гиперчувствительности

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1406641

Country of ref document: EP